Navixizumab (OMP305B83)

For the potential treatment of post platinum ovarian cancer. Navixizumab  is an anti-DLL4/VEGF bispecific antibody designed to inhibit both Delta-like ligand 4 (“DLL4”) in the Notch cancer stem cell pathway as well as vascular endothelial growth factor (“VEGF”) and thereby induce potent anti-tumor responses while mitigating certain angiogenic-related toxicities. STATUS: Partnered – OncXerna Therapeutics Inc.